At a median follow-up of 18 months, the OS rate was 95% and the DFS rate was 88%. 14 Long-term follow-up at a median of 53 ...

Andrea Necchi, MD, discusses how the findings from SunRISe-4 impact other data from the SunRISe group of clinical trials.

Panelists discuss how ruxolitinib has demonstrated efficacy as a second-line treatment strategy for chronic graft-versus-host ...

The phase 3 HypoG-01 trial found moderately hypofractionated radiation therapy had similar lymphedema risk to standard ...

A phase 2 trial of ipilimumab plus nivolumab has met its primary end point of 12-month overall survival rate in non-clear ...

Adjuvant ribociclib plus an aromatase inhibitor is now an FDA-approved treatment in HR-positive, HER2-negative stage II and ...

During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for ...

Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without ...

Inavolisib showed promise in treating patients with PIK3CA-mutated solid tumors, demonstrating favorable safety and disease ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The HIMALAYA study showed that the combination of tremelimumab and durvalumab significantly improved overall survival in ...